PMID- 33162541
OWN - NLM
STAT- MEDLINE
DCOM- 20210118
LR  - 20210118
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 61
IP  - 9
DP  - 2020
TI  - [Treatment of graft-versus-host disease].
PG  - 1395-1401
LID - 10.11406/rinketsu.61.1395 [doi]
AB  - Graft-versus-host disease (GVHD) is one of the most important complications after 
      an allogeneic hematopoietic stem cell transplantation (allo-SCT). The current 
      National Institutes of Health's (NIH) consensus is that clinical manifestations, 
      and not the time to symptomatic onset after transplantation, determine whether 
      the clinical syndrome of GVHD is considered acute or chronic. In the past decade, 
      peripheral blood stem cell transplantation from an unrelated donor can be 
      performed in Japan. Furthermore, poor-risk patients without human leukocyte 
      antigen (HLA)-matched donor can receive allo-SCT from HLA haploidentical donor. 
      Therefore, severe or steroid-refractory GVHD would be increased. Corticosteroid, 
      at a dose of 2 mg/kg, is a standard first-line therapy for acute GVHD. If there 
      is no improvement after the first-line therapy, second-line therapy should be 
      administered immediately. Although anti-thymocyte globulin and mesenchymal stem 
      cells are covered by health insurance in Japan, another treatment options should 
      be determined for steroid-refractory acute GVHD. Furthermore, severe chronic GVHD 
      increases patients' mortality and decreases their quality of life. A number of 
      novel drugs targeting specific biological pathways for GVHD are under 
      development. Currently, more than 60 clinical trials are carried out for the 
      treatment of steroid-refractory GVHD worldwide for drug approval. The 
      accumulation of novel evidence for GVHD treatment is expected to be established.
FAU - Ozawa, Yukiyasu
AU  - Ozawa Y
AD  - Department of Hematology, Japanese Red Cross Nagoya First Hospital.
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (Antilymphocyte Serum)
SB  - IM
MH  - Antilymphocyte Serum
MH  - *Graft vs Host Disease/therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Japan
MH  - Quality of Life
MH  - Transplantation Conditioning
OTO - NOTNLM
OT  - Graft-versus-host disease
OT  - National Institutes of Health consensus
OT  - Steroid-resistant
EDAT- 2020/11/10 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/11/09 05:29
PHST- 2020/11/09 05:29 [entrez]
PHST- 2020/11/10 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.11406/rinketsu.61.1395 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2020;61(9):1395-1401. doi: 10.11406/rinketsu.61.1395.